Locust Walk Acquisition Corporation (LWAC) Quote

And don't forget their WARRANTS --- EFTRW!! BOTH are UP on Etrade's "Extended Hours" display. Meaningless, you say??? Well, not exactly.

$LWAC: This is now $EFTR


Just so you are keeping track.


$18 here in PreMarket



GO $LWAC

This could turn out really well for investors. I’ll follow it.

$60.7 million in expected proceeds from a concurrent private placement.

5k @22 and @27 is more than 10k its 25k. bluffing much?

When volume buys hit the ask we have seen all morning what we can do here. I saw $69.00 premarket. It should be interesting the rest of the day and tomorrow.
$LWAC: Added 5k here at $22

Letsssssssssssss goooooooooooooooooooooo


I want an $RGC big move on this bad boy

Awesome!! Also, warrants for $LWAC also hit nhod 2.15! $LWACW

I am wondering what this will trade tomorrow under new ticker. Could get crazy! ;)

$LWAC: 27 now baby......... $10k !!!!!!!!!


Andddddddddddd halted.

Reallllllllllyyyyyyyyyyyyyy damn



GO $LWAC !!!!!!!!!!

Check warrants out too. $LWACW up over 40%. >>

LWAC stockholders also voted overwhelmingly to approve the other proposals at the special meeting.

The Business Combination is expected to close on or about Wednesday, August 25, 2021. Upon closing, the combined company expects that its common stock and public warrants will commence trading on Nasdaq under the new trading symbols “EFTR” and “EFTRW,” respectively, starting on or about Thursday, August 26, 2021.

https://www.bloomberg.com/press-releases/2021-08-24/locust-walk-acquisition-corp-s-stockholders-approve-business-combination-with-effector-therapeutics-to-create-next-generation

$LWAC

$LWAC: Added 5k here at $22

Letsssssssssssss goooooooooooooooooooooo


I want an $RGC big move on this bad boy



GO $LWAC

eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK 1/2 inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic NSCLC. Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million grant sponsored by the Defense Advanced Research Projects Agency.

Locust Walk Acquisition Shares Jump Premarket on Merger Approval
6:14 am ET August 25, 2021 (Dow Jones) Print


Locust Walk Acquisition Corp. jumped 460% to $49.10 in premarket trading after the company said its stockholders have approved all proposals related to the previously announced business combination with eFFECTOR Therapeutics Inc. at a special meeting of stockholders held Tuesday.

The special purpose acquisition company said 93.2% of the votes cast at the meeting, representing 71.7% of its outstanding shares, voted to approve the business combination.

The merger is expected to close on or about Wednesday. Upon closing, the combined company expects that its common stock and public warrants will begin trading on Nasdaq under the new trading symbols EFTR and EFTRW, respectively, starting on or about Thursday.

Locust Walk received elections to redeem 17 million of its outstanding shares, which will leave $5.2 million in its trust account. Combined with the $60.7 million in expected proceeds from a concurrent private placement, there will be $65.9 million of total cash proceeds from the transaction. As a result, eFFECTOR has waived the requirement that the total cash proceeds equal or exceed $100 million. There will be $53.5 million in cash available to the combined company from the transaction, after deducting transaction fees and expenses.


Chris Wack at chris.wack@wsj.com

Locust Walk Acquisition Shares Trade as High as $69.55 Premarket Wednesday After Shareholders Approved Merger WIth eFFECTOR Therapeutics on Tuesday